Monoclonal antibodies to ING1 isoforms

ABSTRACT

The present invention relates to monoclonal antibodies against the candidate tumor suppressor ING1. A combination of these monoclonal antibodies can detect low levels of endogenous ING1 proteins, and it can also detect at least two different ING1 isoforms, p33ING1b and p47ING1a.

RELATED APPLICATIONS

[0001] This application is a Continuation-In-Part of U.S. patent application Ser. No. 09/532,868, filed Mar. 22, 2000, which was a Divisional application of U.S. patent application Ser. No. 09/258,372, filed Feb. 26, 1999, now U.S. Pat. No. 6,238,918, which was a Continuation of U.S. patent application Ser. No. 08/751,230, filed Nov. 15, 1996, now U.S. Pat. No. 6,117,633, which was a Continuation-In-Part of application Ser. No. 08/569,721, filed Dec. 8, 1995, now U.S. Pat. No. 6,037,121. The content of each of these patents and patent applications is hereby incorporated by reference in its entirety.

[0002] This application also claims the benefit of U.S. Provisional Patent Application Ser. No. 60/208,829, filed Jun. 2, 2000, the entire content of which is hereby incorporated by reference in its entirety.

FIELD OF THE INVENTION

[0003] This invention relates to specific monoclonal antibodies which recognize the isoforms of ING1.

REFERENCES

[0004] U.S. Pat. No. 5,965,398.

[0005] U.S. Pat. No. 5,986,078.

[0006] Boland, D. et al. (2000). A panel of CAb antibodies recognize endogenous and ectopically expressed ING1 protein. Hybridoma 19(2):161-5.

[0007] Garkavtsev, I. & Riabowol, K. (1997). Extension of the replicative life span of human diploid fibroblasts by inhibition of the p331NGI candidate tumor suppressor. Mol. Cell. Biol. 17: 2014-2019.

[0008] Garkavtsev, I., et al. (1997a). Cellular localization and chromosome mapping of a novel candidate tumor suppressor gene (ING1). Cytogenet. & Cell Genet. 76: 176-178.

[0009] Garkavtsev, I., Boland, D., Mai, J., Wilson, H., Veillette, C. and Riabowol, K. (1997b). Specific Monoclonal Antibody Raised Against the p331NGI Tumor Suppressor. Hybridoma 16: 537-540.

[0010] Garkavtsev, I., et al. (1998). The candidate tumour suppressor p331NG′ cooperates with p53 in cell growth control. Nature 391: 295-298.

[0011] Harlow, E. and Lane, D. (1988). Antibodies: A Laboratory Manual, pages 474-510. Cold Spring Harbor Laboratory, NY.

[0012] Laemmli, E. K. (1970). Cleavage of structural proteins during the assembly of the head of the bacteriophage T4. Nature 227: 680-685.

[0013] Loewith, R., Meijer, M., Lees-Miller, S., Riabowol, K. And Young, D. (2000). Three yeast proteins related to the human candidate tumor suppressor p33 (ING1) are associated with histone acetyltransferase activities. Mol. Cell Biol. 20, 3807-3816.

[0014] Maestro, R. et al (1996). Cancer Res. 56: 1146.

[0015] Mitelman, F. et al. (1991). Cytogenet. Cell Genet. 58: 1053.

[0016] Motomura, K. et al. (1988). Genomics 2: 180.

[0017] Ohmori, M., Tasaka, T., Nagai, M., Fujita, M., Takahara, J., Sonoki, T., Riabowol, K., Koeffler, H. And Tohyama, K. (1999). Decreased expression of p331NGI mRNA in lymphoid malignancies. American J. Hematol. 62: 118-119.

[0018] Riabowol, K. et al. (1989). The cdc2 kinase is a nuclear protein that is essential for mitosis in mammalian cells. Cell 57: 393-401.

[0019] Zeremski, M., Hill, J., Kwek, S., Grigorian, I., Gurova, K., Garkavtsev, I., Diatchenko, L., Koonin, E. and Gudkov, A. (1999). Structure and Regulation of the Mouse ing I Gene: Three alternative transcripts encode two PHD finger proteins that have opposite effects upon p53 function. J. Biol. Chem. 274, 32172-32181.

[0020] All of the cited publications and patents are herein incorporated by reference in their entirety to the same extent as if each individual publication, patent application or patent was specifically and individually indicated to be incorporated by reference in its entirety.

BACKGROUND OF THE INVENTION

[0021] The candidate tumor suppressor gene ING1 (INhibitor of Growth 1) was cloned by using a functional cloning strategy (Garkavtsev et al., 1996). Expression of the ING1 gene is regulated through the cell cycle, decreasing as cells exit G₀, increasing late in G₁ and peaking in the S phase (Garkavtsev and Riabowol, 1997). Its expression is down-regulated from 2 to 10-fold in more than 40% of primary breast tumors (Toyama et al., 1999) and in lymphoid malignancies (Ohmori et al., 1999). Overexpression of a construct containing the ING1 gene inhibited cell growth by reducing the fraction of cells which entered into S-phase. Microinjection of the construct blocked the injected cell from entering into S-phase. These results are all consistent with the role of ING1 as a tumor suppressor gene.

[0022] ING1 is located on human chromosome 13q33-34, a region reported to be a site for translocation and deletion in several cancers, including primary gastric cancer, hematologic neoplasms and head and neck squamous cell carcinomas (Motomura et al., 1988; Mitelman et al., 1991; Maestro et al., 1996). To date, a number of ING1 transcripts have been found. Primary and established human cell strains and lines predominantly express three ING1 proteins. p47^(ING1a) and p33^(ING1b) are encoded by two ING1 mRNA isoforms resulted from alternative splicing. p24^(ING1c) is a truncated protein that is believed to be produced by initiation at an internal ATG.

[0023] p33^(ING1b), p47^(ING1a) and p24^(ING1c) share the same C-terminal portion encoded by a common 3′ exon. This shared region contains a PHD domain and a nucleus localization signal. The PHD domain has the consensus sequence Of Cys₄-His-Cys₃. This evolutionarily conserved domain is predicted to chelate two Zn²⁺ ions and is similar to, but distinct from, other zinc binding motifs. PHD domains have been found in many different proteins, including transcription factors and other proteins implicated in chromatin-mediated transcriptional regulation, but the function of the PHD domains has not been determined.

[0024] ING1 appears to interact with other cellular factors to regulate the growth properties of cells. For example, the growth-inhibition activity of ING1 is dependent on another tumor suppressor, p53, and vice versa. Neither of these two genes alone causes growth inhibition if the other one is suppressed. Expression of both genes in a mammalian cell results in normal growth regulation and anchorage-dependent growth, and apoptosis is induced in response to irreversible DNA damage and other cellular insult. Inhibition of expression of either gene results in a loss of cellular growth control, anchorage-independent growth, inhibition of apoptosis and resistance to radiation and cytotoxic drugs. Moreover, regulation of gene expression by p53, such as of the p21^(WAF1) gene, also depends on the expression of ING1 (Garkavtsev et al., 1998).

[0025] To investigate the roles of the ING1 isoforms and the interaction with p53 or other factors, it is important to have antibodies which can detect the endogenous ING1 proteins, as well as antibodies which recognize the ING1 isoforms. We previously reported a monoclonal antibody, CAb1, which specifically recognizes native and denatured p33ING1b in ELISA and Western blot analyses, respectively (Garkavtsev et al., 1997b). CAb1 is also useful for cellular localization of overexpressed p33ING1 protein by indirect immunofluorescence. However, CAb1 is not sensitive enough to detect the low level endogenous ING1 protein. Moreover, although CAb1 recognizes p33ING1b and a GST-p33ING1 fusion protein, it does not recognize other ING1 isoforms such as p47ING1a and p24ING1c. It is thus desirable to make other monoclonal antibodies against ING1 which can achieve these goals.

SUMMARY OF THE INVENTION

[0026] In the present invention, a panel of monoclonal antibodies, CAb2 to CAb10, were raised against ING1. Combinations of CAbs 1-9 are sensitive enough to detect the endogenous ING1 proteins in normal human diploid fibroblasts and various brain tumor cell lines. A combination of CAbs 1-4 recognize at least two ING1 isoforms. Therefore, this invention provides for useful monoclonal antibodies against ING1, methods to detect endogenous ING1 proteins and methods to detect different ING1 isoforms.

[0027] Accordingly, one aspect of the present invention provides a monoclonal antibody which recognizes an epitope of an ING1 protein. In particular, the monoclonal antibody is selected from the group consisting of CAb1, CAb2, CAb3, CAb4, CAb5, CAb6, CAb7, CAb8, CAb9 and CAb10.

[0028] The monoclonal antibody is preferably not CAb1. Therefore, the monoclonal antibody is preferably selected from the group consisting of CAb2, CAb3, CAb4, CAb5, CAb6, CAb7, CAb8, CAb9 and Cab10.

[0029] Also provides are cells which produce the monoclonal antibody which recognizes an epitope of an ING1 protein. In particular, the monoclonal antibody is selected from the group consisting of CAb1, CAb2, CAb3, CAb4, CAb5, CAb6, CAb7, CAb8, CAb9 and CAb10. The monoclonal antibody is preferably not CAb1. Therefore, the monoclonal antibody is preferably selected from the group consisting of CAb2, CAb3, CAb4, CAb5, CAb6, CAb7, CAb8, CAb9 and CAb10.

[0030] Another aspect of the present invention provides a method of detecting an ING1 protein in a cell using monoclonal antibodies, comprising:

[0031] (a) selecting a cell;

[0032] (b) applying to the cell, extract of the cell, or a form of the cell suitable for the detection of the ING1 protein an anti-ING1 monoclonal antibody or a combination of anti-ING1 monoclonal antibodies in an amount sufficient to detect the ING1 protein in said cell; and

[0033] (c) detecting the ING1 protein.

[0034] To specifically detect the ING1 protein, the method can further comprise the steps of repeating step (b) wherein the antibody or antibody mix is pre-treated with an ING1 protein and comparing the result obtained with the treated antibody to that obtained with the untreated antibody. If pre-treatment with an ING1 protein results in disappearance of the detected ING1 level, the signal detected with the untreated antibody is completely specific to the ING1 protein used to treat the antibody. Similarly, if the pre-treatment results in a reduction in the signal, then the difference between levels detected by the untreated and pre-treated antibody is specific to the ING1 protein used to treat the antibody.

[0035] The anti-ING1 monoclonal antibody used in this method is preferably an antibody selected from the group consisting of CAb2, CAb3, CAb4, CAb5, CAb6, CAb7, CAb8, CAb9 and CAb10. More preferably, the antibody is a combination of two or more antibodies selected from the group consisting of CAb1, CAb2, CAb3, CAb4, CAb5, CAb6, CAb7, CAb8, CAb9 and CAb10. Most preferably, the combination is a mixture of CAb1 to Cab10.

[0036] This method can be used to detect endogenous ING1 or ectopically expressed ING1 proteins.

[0037] Yet another aspect of the present invention provides for a method of detecting at least two different isoforms of ING1 with monoclonal antibodies, comprising using an anti-ING1 monoclonal antibody or a combination of anti-ING1 monoclonal antibodies under conditions which result in the detection of at least two isoforms of ING1. The combination if preferably two or more antibodies selected from the group consisting of CAb1, CAb2, CAb3, CAb4, CAb5, CAb6, CAb7, CAb8, CAb9 and CAb10. More preferably, the combination is a mixture of CAb1, CAb2, CAb3, and CAb4. The ING1 isoforms may be ectopically or endogenously expressed in a cell.

[0038] Also provided are kits comprising anti-ING1 monoclonal antibodies and secondary antibodies which recognize the anti-ING1 monoclonal antibodies. These kits are useful in detecting ING1 proteins in immunofluorescence assays, Western blot assays, ELISAs or any antibody-mediated detection method established in the art. Accordingly, the kit may further comprise additional reagents or devices for each individual assay. For example, a kit for Western blot assay my further comprise reagents for making the SDS-PAGE gel as well as blot membranes and buffers for the blotting.

[0039] Another aspect of the present invention provides a method of diagnosing a disease or medical condition in an animal associated with aberrant levels of an ING1 protein, comprising determining levels of the ING1 protein with a monoclonal antibody or a combination of monoclonal antibodies which is capable of recognizing the ING1 protein. The disease is preferably a tumor. The levels of ING1 proteins can be determined using a sample obtained from the animal, such as a biopsy sample of the tumor. The animal is preferably a human.

DETAILED DESCRIPTION OF THE INVENTION

[0040] This invention relates to monoclonal antibodies against the ING1 candidate tumor suppressor.

[0041] As used herein, “ING1” refers to an ING1 gene. An ING1 gene is a gene which has substantial homology with the human ING1 gene and which encodes a protein with ING1 biological activities.

[0042] A gene has substantial homology with the human ING1 gene if the gene encodes a protein which has at least about 60% amino acid sequence identity with p47ING1a (SEQ ID NO:2), p33ING1b (SEQ ID NO:4) or p24ING1c (SEQ ID NO:5). The sequence identity is more preferably at least about 70%, still more preferably at least about 80%, and most preferably at least about 90%. Alternatively, a gene having substantial homology with the human ING1 gene is the gene hybridizes under stringent conditions to the human ING1 gene having the sequence of SEQ ID NO: 1 (p47ING1a gene) or SEQ ID NO:3 (p33ING1b gene). “Stringent conditions”, in turn, refer to hybridization conditions at a minimal stringency equivalent to 0.1 times SSC, 0.1% SDS and 55° C. The stringency is preferably 0.1 times SSC, 0.1% SDS and 60° C., and more preferably 0.1 times SSC, 0.1% SDS and 65° C.

[0043] “ING1 biological activities” means at least one of the following: (1) immunological cross-reactivity with a polyclonal antiserum raised against the native p47ING1a, p33ING1b or p24ING1c protein; or (2) an activity to inhibit cell proliferation or tumor formation, which activity is possessed (but maybe at a different level) by the native p47ING1a, p33ING1b or p24ING1c protein.

[0044] Cross-reactivity can be determined by any method established in the art, such as diffusion assays or ELISA. Assays for cell proliferation inhibition or tumor formation inhibition are also well-known to skilled artisans (for example, see U.S. Pat. Nos. 5,965,398 and 5,986,078). Examples of these activities include the activity to inhibit cell growth as measured by the decrease of the S-phase fraction in a population of cells, the activity to inhibit focus formation in soft agar, the activity to inhibit cell proliferation as determined by the number increase of cells in a population over time, the activity to reduce tumor size or mass, and the activity to inhibit tumor cell metastasis.

[0045] While ING1 was originally cloned from a human cDNA library, mouse and yeast ING1 homologs have also been identified by nucleic acid sequence similarity (Zeremski et al., 1999; Loewith et al., 2000). It is contemplated that ING1 also encompasses the mouse and yeast ING1 genes.

[0046] As used herein, “ING1 protein” or “ING1 gene product” refer to a protein encoded by an ING1 gene. Examples of ING1 proteins include, but are not limited to, p47ING1a, p33ING1b and p24ING1c.

[0047] A “disease or medical condition associated with aberrant levels or an ING1 protein” is a disease or medical condition which is associated with abnormally high or abnormally low levels of a ING1 protein. For example, as previously disclosed, ING1 is down-regulated from 2 to 10-fold in more than 40% of primary breast tumors (Toyama et al., 1999) and in lymphoid malignancies (Ohmori et al., 1999).

[0048] A “sample” is a specimen obtained from an animal, such as blood, urine, a piece of tissue, hair, saliva, and the like.

[0049] To raise monoclonal antibodies against the ING1 proteins, a GST-ING1 fusion protein was used to immunize BALB/c mice, and spleen cells from the immunized mice were fused with Sp2/mIL6 myeloma cells to make hybridomas. This GST-ING1 fusion protein was expressed from a plasmid containing nucleotides 161 to 1143 of the human ING1 gene. Synthesis of this plasmid and preparation of this GST-ING1 fusion protein were performed as previously described (Garkavtsev et al., 1997b). Hybridomas were produced as described in Materials and Methods.

[0050] In three previous attempts, it had proven difficult to isolate stable colonies of hybridomas expressing antibodies directed against the ING1 proteins. Many positive colonies were detected initially, but they were unstable and rapidly lost their titer. We noted during the course of these experiments that stable hybridoma lines came from those mice which did not have the highest titer as determined by ELISA. Moreover, we initially selected the mice whose sera had high reactivity with the ING1 portion of the GST-ING 1 fusion protein and reasonably low cross-reactivity with GST. However, hybridoma fusion results indicated that stable hybridoma clones were most frequently derived from the mice with high reactivity to ING1 and medium to high GST cross-reactivity.

[0051] Nine hybridomas were obtained which reacted specifically with ING1 but not the GST moiety. The antibodies produced by these nine hybridomas are designated CAb2 to CAb10, respectively. High levels of specificity of these antibodies are demonstrated in Example 1. Thus, each of CAbs 1-4 could detect the GST-ING1 fusion protein at concentrations as low as 5 ng/ml, while none of them recognized GST, even at 500 ng/ml.

[0052] To determine if these antibodies can detect endogenous ING1, a mixture of CAbs 1-9 was used to stain Hs68 fibroblasts or brain cancer cell lines. As used herein, “endogenous ING1” refers to the ING1 proteins expressed in a cell which has not received any exogenously added ING1 gene, RNA or protein. As shown in Example 2, the antibody mix was able to detect the endogenous ING1 proteins in both Hs68 fibroblasts and the brain cancer cells. The antibody mix stained both the nucleus and cytoplasm, but when the mix was pre-treated with the GST-ING1 fusion protein, the nuclear signal disappeared, indicating that the nuclear staining was specific for ING1. This result is consistent with the previous report that the ING1 protein is localized in the nucleus.

[0053] These antibodies are also useful in Western blot analyses. A mixture of CAb1-4 was used to stain Western blots of various cell extracts (Example 3) and recognized p33ING1b in cells transfected with a vector containing the ING1 sequence. The antibody mix also recognize the same band in a variety of brain tumor cell lines and a weak band corresponding to p47ING1a. Therefore, these antibodies recognize at least two isoforms of ING1 and will be useful in determining the functions and mechanisms of the isoforms. For example, cellular extracts can be immunoprecipitated with an antibody against another protein which is suspected of interacting with the ING1 proteins, and the immunoprecipitates can be blotted with a mixture of the CAb1-4 antibodies to determine which isoforms are involved.

[0054] The activity of each individual antibody in Western blots is shown in Example 4. Every antibody recognized p33ING1b. The relative activity of the antibodies in ELISA, immunofluorescence and Western blot is summarized in Table 1.

[0055] It is contemplated that more monoclonal antibodies may be produced using different portions of ING 1 or different ING1 isoforms as antigens. The resulting hybridomas can be tested as described herein in order to obtain antibodies which can distinguish the ING1 isoforms, or to obtain antibodies with higher sensitivity. Also contemplated is the identification of antibodies which recognize different portions of the ING1 proteins. Such antibodies can be used in structure-function analysis of the ING1 proteins.

[0056] Recombinant derivative antibodies can be made using the hybridomas described herein according to well-known genetic engineering methods. A review for these methods can be found in Winter et al., Nature 349: 293, 1991. For example, the DNA fragment coding for the variable regions of the monoclonal antibodies can be obtained by polymerase chain reactions (PCR). The PCR primers can be oligonucleotides which are complementary to the constant regions of the heavy chain or light chain, and the PCR template can be the total cDNA or genomic DNA prepared from the hybridomas. Alternatively, a cDNA library can be prepared from the hybridomas and screened with probes which correspond to the constant regions of immunoglobulin heavy chain or light chain to obtain clones of the heavy chain or light chain produced by the particular hybridoma.

[0057] Subsequently, the DNA fragment for the variable regions can be inserted into an expression vector and joined in frame with the cDNA sequences of a selected constant region. The constant region can be the human constant sequences to make humanized antibodies, the goat constant sequences to make goat antibodies, the IgE constant sequences to make IgE which recognizes the ING1 proteins, and the like. Thus, antibodies with the same antigen recognition ability but different constant regions can be produced. Such antibodies will be useful, for instance, in indirect immunofluorescence experiments where the choice of secondary antibodies is limited. For example, if an anti-p53 antibody and an anti-ING 1 antibody will be used in the same experiment but both are mouse antibodies of the same isotype, it will not be easy to distinguish the two signals. An anti-ING1 antibody of another kind of constant region will solve this problem.

[0058] The monoclonal antibodies can also be used to produce anti-idiotypic antibodies. To make anti-idiotypic antibodies, hybridoma cells for each monoclonal antibody can be used as antigens to immunize an animal for antibody productions. Alternatively, polypeptides corresponding to the variable region of the monoclonal antibodies can be expressed in a suitable host system using DNA fragments prepared as described above, and used as antigens in immunizations.

[0059] The following examples are offered to illustrate this invention and are not to be construed in any way as limiting the scope of the present invention.

EXAMPLES

[0060] In the examples below, the following abbreviations have the following meanings. Abbreviations not defined have their generally accepted meanings.

[0061] ° C.=degree Celsius

[0062] hr=hour

[0063] min=minute

[0064] μM=micromolar

[0065] mM=millimolar

[0066] M=molar

[0067] ml=milliliter

[0068] μl=microliter

[0069] mg=milligram

[0070] μg=microgram

[0071] PAGE=polyacrylamide gel electrophoresis

[0072] rpm=revolutions per minute

[0073] FBS=fetal bovine serum

[0074] DTT=dithiothrietol

[0075] SDS=sodium dodecyl sulfate

[0076] PBS=phosphate buffered saline

[0077] DMEM=Dulbecco's modified Eagle's medium

[0078] α-MEM=α-modified Eagle's medium

[0079] β-ME=β-mercaptoethanol

[0080] DMSO=dimethylsulfoxide

[0081] ELISA=enzyme-linked immunosorbent assay

[0082] CMV=cytomegalovirus

[0083] GST=glutathione-S-transferase

[0084] IPTG=isopropyl beta-D-thiogalactoside

MATERIALS AND METHODS

[0085] HYBRIDOMA

[0086] Four female BALB/c mice (5- to 6-weeks old) were boosted with 10 μg each of recombinant GST-ING1 protein prepared as previously described (Garkavtsev et al., 1997b). The protein in the first injection was emulsified with Freund's complete adjuvant and with Freund's incomplete adjuvant for subsequent injections, with injections being done every three weeks. After a series of three injections the sera were tested by ELISA and 2 mice with the best titers were selected for fusion.

[0087] Four days before the fusion, the mice were boosted by tail vein injections with 5 μg of GST-ING1. On the day of the fusion, spleens were removed from the mice, and spleen cells were isolated and fused with Sp2/mIL6 myeloma cells using polyethylene glycol 1500 as the fusing agent. The cells were resuspended in media containing hypoxanthine/aminopterin/thymidine (HAT) to select for hybridoma growth and were plated into 96-well tissue culture plates. After 10 to 14 days the colonies were tested by ELISA and positive colonies were subcloned twice and grown up to larger volumes for further testing. The cells were adapted into SFM, a serum free medium (Gibco BRL) and allowed to produce concentrated supernatant for use in western blotting and indirect immunofluorescence assays following microinjection of ING1 expression construct into various cell types. All the cell lines that were obtained grew well in SFM.

[0088] ELISA

[0089] The ELISA method was used to test emergent colonies for titer. 100 μl aliquots of cell supernatant were added to individual wells of 96 well ELISA plates previously coated with GST-ING1 and incubated for 1 hour at 37 ° C. Plates were then washed with PBS/0.1% Tween 20, pH 7.4 (wash buffer). Goat anti-mouse IgG-biotin was diluted to 1/1000 with 1% BSA/PBS/0.1% Tween 20, pH7.4 (diluting buffer) and was added to the wells, incubated for 1 hour at 37 ° C. and washed 5 times with wash buffer. Strepavidin-alkaline phosphatase was diluted to 1/1000 with diluting buffer, incubated and washed as per the previous step. Paranitrophenylphosphate in substrate buffer was used as the developing agent. The plate was read at OD 405 and any positives were re-tested two days later against both GST-ING1 and GST to determine cross-reactivity. To determine the subisotypes of the various hybridoma lines a MouseHybridoma-Subtyping Kit (Boehringer Mannheim) was used according to the manufacturer's directions.

[0090] MICROINJECTION, FIXATION AND IMMUNOFLUORESCENCE

[0091] For microinjection studies, Hs68 cells were plated on acid-washed 1 cm glass coverslips and allowed to grow for 48 hr prior to microinjection. Sense or antisense orientations of the a or b forms of ING1 cDNA cloned downstream of the CMV promoter in the pC1 vector (Promega), or the vector alone, were diluted to 0.1 mg/ml in sterile PBS as described (Garkavtsev et al., 1996), and solutions were centrifuged for 5 minutes at 14,000×g to remove particulate material. Solutions containing expression or control plasmids were injected into the nuclei of cells using needle microcapillaries and cells were subsequently incubated in complete medium for 24 hr.

[0092] After this time period, cells were fixed by immersion in 3.7% formaldehyde diluted in PBS (pH 7.0) for 10 min at room temperature (RT) and permeabilized with 0.5% Triton X-100 in PBS for an additional 10 min at RT. Coverslips were stored at 4° C. overnight (12-24 hr) in sterile PBS prior to staining. In the case of controls and cells injected with antisense constructs, no staining above background levels was observed. For subsequent studies, only uninjected cells and cells expressing ING1 were recorded photographically following staining for ING1 protein.

[0093] Hybridoma supernatants derived from 10 individually isolated monoclonal antibodies including CAb1 (Garkavtsev et al., 1997b) were used undiluted as primary antibodies and staining was compared to a negative control consisting of mouse myeloma supernatant. A polyclonal rabbit antiserum diluted 1:200 that has been described previously (Garkavtsev et al., 1997a) was used as a positive control for indirect immunofluorescence. Coverslips were incubated with 50 μl of primary antibody solution for 30 minutes at 37° C., washed 3 times for 10 min in PBS, and incubated with biotinylated goat anti-rabbit IgG or biotinylated goat anti-mouse IgG that were diluted 1:200 with PBS containing 0.1% bovine serum albumin (BSA). Coverslips were again washed 3 times for 10 minutes in PBS and incubated with a 1:150 dilution of Strepavidinconjugated Texas Red (in 0.1% BSA/PBS) for 30 min before washing and mounting of coverslips in Gelvatol containing n-propyl gallate as an antiquenching agent as described (Riabowol et al., 1989). Cells were visualized on a Zeiss Axiophot microscope and images were recorded using Kodak Tri X-100 film.

[0094] WESTERN BLOTTING

[0095] Individual 10 cm petri dishes of cells were harvested in 0.5 ml Laemmli sample buffer (Laemmli, 1970) and equivalent protein loading was estimated by Coomassie Brilliant Blue staining of protein samples resolved using sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE). For western blots, samples were resolved by SDS-PAGE and transferred to nitrocellulose membranes as described (Harlow and Lane, 1988). The membranes were blocked overnight in phosphate buffered saline (PBS) containing 0.1% Tween 20 (PBS-Tween) and 5% powdered skim milk. All subsequent incubations were performed for 30 minutes at room temperature and washes were performed three times each for 5 minutes in PBS-Tween. Membranes were incubated in primary antibodies (polyclonal a-GST-ING1, 1:1000 to 1:5000; monoclonal a-ING1 tissue culture supernatants diluted 1:1 with PBS-Tween-5% non-fat milk), washed, incubated with secondary antibodies (biotinylated goat a-rabbit or mouse, 1:1000; Amersham), washed and incubated with tertiary reagent (strepavidin-conjugated horseradish peroxidase, 1:1000; Amersham). After a final wash, membranes were treated with chemiluminescent reagent (ECL reagent, Amersham) and exposed for 3 minutes to 1 hour to X-ray film (Kodak OMAT).

[0096] CELL TRANSFECTION

[0097] For transfection of primary human fibroblasts (Hs68) or the brain tumor line SNB19, cells were grown in 15 cm petri dishes (Corning) in Dulbecco's Modified Eagles medium (DMEM) (Gibco) supplemented with 10% fetal bovine serum (FBS) (Gibco) to approximately 85 to 90% confluence. Each dish contained cells for one transfection. Cells were trypsinized, pelleted and resuspended in 400 μl DMEM without FBS. 10 μg of either pCl-ING1b or pCl vector (Promega) plus 10 μg of sheared salmon sperm DNA (Amersham Pharmacia) were made up to 100 μl in DMEM without FBS and this was added to each cell suspension. Each 500 μl aliquot of cell suspension plus DNA mix was transferred to a sterile 4 mm gap electroporation cuvette (BTX). Electroporator (BioRad) settings were 250 V, 960 μFd and capacitance, EXT (extender). After electroporation, cells were transferred to 10 cm dishes with 10 ml DMEM containing 10% FBS for 24 hours and were then re-fed. After a further 24 hours the cells were harvested for protein analysis by scraping in Laemmli sample buffer and boiling for 1 min.

Example 1 Detection of ING1 in ELISA by CAb1-4

[0098] The ELISA plate was coated with GST-ING1 or GST in alternate rows. The concentration of GST-ING1 or GST ranged from 5, 10, 5, 100 to 500 ng/ml in each well. CAb1-4 was used to detect GST-ING1 or GST as described in Materials and Methods, and the conditioned medium from Sp2/mIL6 myelomas served as a negative control.

[0099] The results indicate that CAb1-4 were all capable of detecting the lowest level of GST-ING1 while none of them cross-reacted with GST, even when the concentration of GST was as high as 500 ng/ml. The negative control yielded no signal as expected. Therefore, these monoclonal antibodies are highly specific for the ING1 protein.

[0100] CAb5-10 were also tested and each staining intensity was measured with a Biomek 1000 ELISA reader. The resulting readings were used to generate the ELISA ranking shown in Table 1. Each of the monoclonal antibodies displayed a titer at least comparable to that of a mouse polyclonal antiserum, the titer of which is arbitrarily set to be 1.00.

Example 2 Indirect Immunofluorescence of Endogenous and Ectopically Expressed ING1

[0101] To test if the CAbs can detect ectopically expressed ING1 proteins in indirect immunofluorescence assays, individual cells were microinjected with an ING1 expression construct containing the CMV promoter. The cells were then fixed and stained with nuclear staining as well as different ING1 antibodies. A rabbit polyclonal antibody against ING1 proteins yielded strong staining signals, indicating that the injected gene was expressed at a high level. The mixture of CAb1-4 or each monoclonal antibody alone was also capable of generating positive staining. The results are summarized in Table 1 where the relative strength of nuclear staining is listed. The results indicate that these antibodies or antibody mixtures can detect the ING1 proteins in individual cells.

[0102] To determine if these antibodies can detect endogenous ING1 proteins, a mixture of CAb1-9 was used to stain Hs68 fibroblasts which are known to express ING1 proteins. Clear nuclear and cytoplasmic signals were observed. However, when the antibody mix was blocked with the GST-ING1 fusion protein prior to staining, the nuclear signal, but not the cytoplasmic signal, was markedly reduced. This is consistent with the previous observation that ING1 products are localized to the nucleus. Similarly, brain cancer cell lines known to express much higher levels of ING1 show clear nuclear signals when stained with the monoclonal mix. Therefore, these antibodies are sensitive enough to detect endogenous ING1 proteins.

Example 3 Western Blot Assays of Endogenous and Ectopically Expressed ING1 Proteins with CAb Mixtures

[0103] An equal mixture of CAb1-4 was used to detect ING1 in extracts of transfected fibroblast cells, bacterial cells harboring an expression construct for ING1, and a number of human brain tumor cell lines in Western blot assays.

[0104] Hs68 fibroblasts transfected with pC1-ING1b produced a clear band migrating at a position expected of p33ING1b. In contrast, Hs68 fibroblasts transfected with pC1 vector alone showed essentially no signal at this position. Similarly, bacterial lysates from bacteria harboring an IPTG-inducible GST-ING1 expression construct yielded a strong 58 kD band which corresponds to the GST-ING1 fusion protein band only in the presence of IPTG. In the absence of IPTG, no signal could be observed. Clearly, the monoclonal antibodies can be used in Western blot assays to detect ING1 proteins.

[0105] Whole cell lysates of various human brain tumor lines were also used to test the ING1 antibodies. These tumor lines include SF188, U251, U373, TE671, SNB19, HBS683 and U343. The CAb mix recognized a 33kD band and a weak band at approximately 47 kD, which corresponds to p47ING1a. Therefore, the CAb mix recognizes at least two isoforms of ING1.

Example 4 Western Blot Assays with Individual CAb1-9

[0106] The ability of each individual antibody to recognize ING1 in Western blot assays was assessed using the conditioned medium from the myeloma line Sp2/mIL6 as a negative control. The results show that each of CAb1-9 binds to p33ING1b to a different degree. The relative strengths of the antibodies were estimated visually and included in Table 1, where the strength of the mouse polyclonal antiserum was arbitrarily assigned the value of 1. TABLE 1 Characterization of the CAb line of monoclonal antibodies by sub-isotyping, comparative titer, intensity and degree of nuclear localization and band mobility via western blotting. MOUSE RABBIT NAME CAb 1 CAb 2 CAb 3 CAb 4 Cab 5 CAb 6 CAb 7 CAb 8 CAb 9 CAb 10 POLY POLY SUB-ISOTYPE IgG2a IgG1 IgG1 IgG1 IgG2a IgG1 IgG1 IgG1 IgG1 IgM — — ELISA RANKING 1.00 1.13 1.78 1.74 0.85 1.92 2.30 2.36 1.14 1.10 1.00 — NUCLEAR + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + NOT + + + + + + + LOCALIZATION TESTED (IMMUNO- FLUORESCENCE) WESTERN BLOT + + + + + + + + + + + + + + + + + + + + + + + + + + + + NOT + NOT 33 kD BAND TESTED TESTED STRENGTH

[0107]

1 5 1 2886 DNA Homo sapiens CDS (433)..(1701) 1 tgcgctcggg ggggcgcggg cagatcgctg gcttggagag gactgtggca ggtgagagga 60 cctgtgcgtc gttctctgca gacctggccg ccccgggtgt cagagagagg tggcgagttc 120 gtgtccgccg ggaattgttg gctgttgggg aaactttcct gcgaggtcag tcaaggcttt 180 gggggctctg ttttgaatgt ggatcaccac tcggagttta ctaatgttta caaggctgcg 240 cagtagggaa acggaagagt tgggtggggg caaaaaaaaa aattgaccgc tgtccccgaa 300 agtactagac gcctctgccg ggaaggcgcc cctgcgcgtt ctatccgaga cgtagcttcg 360 cagcgaattt tataggaact tcattagcat attatggaac gtcccgcctc agccccccag 420 tagttggctg tg atg tcc ttc gtg gaa tgt cct tat cat tcc cct gcg gaa 471 Met Ser Phe Val Glu Cys Pro Tyr His Ser Pro Ala Glu 1 5 10 cga ttg gtc gct gag gcg gat gaa ggc ggg cct agc gca ata act ggt 519 Arg Leu Val Ala Glu Ala Asp Glu Gly Gly Pro Ser Ala Ile Thr Gly 15 20 25 atg ggt ctg tgt ttc cgc tgt ctt ctt ttt tct ttt tcg ggg agg agc 567 Met Gly Leu Cys Phe Arg Cys Leu Leu Phe Ser Phe Ser Gly Arg Ser 30 35 40 45 ggg gtg gag ggt gga cga gtt gat ttg aac gtc ttc ggg tcg ctc ggc 615 Gly Val Glu Gly Gly Arg Val Asp Leu Asn Val Phe Gly Ser Leu Gly 50 55 60 ctc cag cct tgg att ggt tct tct cgc tgc tgg ggc ggg ccg tgc tct 663 Leu Gln Pro Trp Ile Gly Ser Ser Arg Cys Trp Gly Gly Pro Cys Ser 65 70 75 tcc gcc ctg cgg tgt ggt tgg ttc tcc tcc tgg cct ccg ccc tcc aaa 711 Ser Ala Leu Arg Cys Gly Trp Phe Ser Ser Trp Pro Pro Pro Ser Lys 80 85 90 tcg gcg att ccc ata ggc ggc ggc tct cgg ggt gcg ggg cga gtc tcc 759 Ser Ala Ile Pro Ile Gly Gly Gly Ser Arg Gly Ala Gly Arg Val Ser 95 100 105 cgc tgg cct cct ccc cat tgg ctg gag gcc tgg cgg gtg tcg ccc cgg 807 Arg Trp Pro Pro Pro His Trp Leu Glu Ala Trp Arg Val Ser Pro Arg 110 115 120 125 ccc ctc tcc ccg ctc agc ccg gcc act ttc ggg cgc gga ttt ata gca 855 Pro Leu Ser Pro Leu Ser Pro Ala Thr Phe Gly Arg Gly Phe Ile Ala 130 135 140 gta gca gtg atc ccg ggc ctg tgg gct cgg ggc cgg ggc tgc agt tcg 903 Val Ala Val Ile Pro Gly Leu Trp Ala Arg Gly Arg Gly Cys Ser Ser 145 150 155 gac cgc ctc ccg cga ccc gcg ggg ccg gct cgg aga cag ttt cag gcc 951 Asp Arg Leu Pro Arg Pro Ala Gly Pro Ala Arg Arg Gln Phe Gln Ala 160 165 170 gca tct ttg ctg acc cga ggg tgg ggc cgc gcg tgg ccg tgg aaa cag 999 Ala Ser Leu Leu Thr Arg Gly Trp Gly Arg Ala Trp Pro Trp Lys Gln 175 180 185 atc ctg aag gag cta gac gag tgc tac gag cgc ttc agt cgc gag aca 1047 Ile Leu Lys Glu Leu Asp Glu Cys Tyr Glu Arg Phe Ser Arg Glu Thr 190 195 200 205 gac ggg gcg cag aag cgg cgg atg ctg cac tgt gtg cag cgc gcg ctg 1095 Asp Gly Ala Gln Lys Arg Arg Met Leu His Cys Val Gln Arg Ala Leu 210 215 220 atc cgc agc cag gag ctg ggc gac gag aag atc cag atc gtg agc cag 1143 Ile Arg Ser Gln Glu Leu Gly Asp Glu Lys Ile Gln Ile Val Ser Gln 225 230 235 atg gtg gag ctg gtg gag aac cgc acg cgg cag gtg gac agc cac gtg 1191 Met Val Glu Leu Val Glu Asn Arg Thr Arg Gln Val Asp Ser His Val 240 245 250 gag ctg ttc gag gcg cag cag gag ctg ggc gac aca gcg ggc aac agc 1239 Glu Leu Phe Glu Ala Gln Gln Glu Leu Gly Asp Thr Ala Gly Asn Ser 255 260 265 ggc aag gct ggc gcg gac agg ccc aaa ggc gag gcg gca gcg cag gct 1287 Gly Lys Ala Gly Ala Asp Arg Pro Lys Gly Glu Ala Ala Ala Gln Ala 270 275 280 285 gac aag ccc aac agc aag cgc tca cgg cgg cag cgc aac aac gag aac 1335 Asp Lys Pro Asn Ser Lys Arg Ser Arg Arg Gln Arg Asn Asn Glu Asn 290 295 300 cgt gag aac gcg tcc agc aac cac gac cac gac gac ggc gcc tcg ggc 1383 Arg Glu Asn Ala Ser Ser Asn His Asp His Asp Asp Gly Ala Ser Gly 305 310 315 aca ccc aag gag aag aag gcc aag acc tcc aag aag aag aag cgc tcc 1431 Thr Pro Lys Glu Lys Lys Ala Lys Thr Ser Lys Lys Lys Lys Arg Ser 320 325 330 aag gcc aag gcg gag cga gag gcg tcc cct gcc gac ctc ccc atc gac 1479 Lys Ala Lys Ala Glu Arg Glu Ala Ser Pro Ala Asp Leu Pro Ile Asp 335 340 345 ccc aac gaa ccc acg tac tgt ctg tgc aac cag gtc tcc tat ggg gag 1527 Pro Asn Glu Pro Thr Tyr Cys Leu Cys Asn Gln Val Ser Tyr Gly Glu 350 355 360 365 atg atc ggc tgc gac aac gac gag tgc ccc atc gag tgg ttc cac ttc 1575 Met Ile Gly Cys Asp Asn Asp Glu Cys Pro Ile Glu Trp Phe His Phe 370 375 380 tcg tgc gtg ggg ctc aat cat aaa ccc aag ggc aag tgg tac tgt ccc 1623 Ser Cys Val Gly Leu Asn His Lys Pro Lys Gly Lys Trp Tyr Cys Pro 385 390 395 aag tgc cgg ggg gag aac gag aag acc atg gac aaa gcc ctg gag aaa 1671 Lys Cys Arg Gly Glu Asn Glu Lys Thr Met Asp Lys Ala Leu Glu Lys 400 405 410 tcc aaa aaa gag agg gct tac aac agg tag tttgtggaca ggcgcctggt 1721 Ser Lys Lys Glu Arg Ala Tyr Asn Arg 415 420 gtgaggagga caaaataaac cgtgtattta ttacattgct gcctttgttg aggtgcaagg 1781 agtgtaaaat gtatattttt aaagaatgtt agaaaaggaa ccattccttt catagggatg 1841 gcagtgattc tgtttgcctt ttgttttcat tggtacacgt gtaacaagaa agtggtctgt 1901 ggatcagcat tttagaaact acaaatatag gtttgattca acacttaagt ctcagactga 1961 tttcttgcgg gaggaggggg actaaactca acctaacaca ttaaatgtgg aaggaaaata 2021 tttcatttag cttttttatt ttaatacaag taatattatt actttatgaa caattttttt 2081 taattggcca tgtcgccaaa aatacagcct atagtaaatg tgtttcttgc tgccatgatg 2141 tatatccata taacaattca gtaacaaagg tttaaagttt gaagattatt ttttaaaaag 2201 gtaaatggtt aaattttaca tgacagatat tttatttatt ggcctgttcc ccaaatggcc 2261 attttaaaat gcttgggtac acttctctta agtggtctag tcaaggaacc tcaagtcatg 2321 cttttgctat caccaatcat agtgtaccca tctttaattt atatcaggtg tataaatgta 2381 catttccaaa tgaacttgca cttgttatat tataattgga agtgcagtca gcagatgctg 2441 ttgtgaagct aatgtcacaa ttatgtgcaa aggtgtgctt cctgctgtat gtgagctgta 2501 aaaatgttac gtgaagaaat aaatgaaact tggccagttt gttcctctag tagtatattt 2561 aattttgaca taagtaactt ttaaaatttg tcttaaaaat ttatacacca gcaatttaga 2621 caaagcctta agcaaatttt gtattattgt tctcacttat tattaataat gaagtagaag 2681 ttacttaatt gccagcaaat aaatacgtgt caaaaaagaa tctgtattca gaccctgggt 2741 caggaaatta ctgcccactt gtcaagttca gcccaccatc tgtttgaaca ttatatgaag 2801 tttaaatttt agtgtccata aataaagttt cagcggaaca caaaaaaaaa aaaaaaaaaa 2861 aaaaaaaaaa aaaaaaaaaa aaaaa 2886 2 422 PRT Homo sapiens 2 Met Ser Phe Val Glu Cys Pro Tyr His Ser Pro Ala Glu Arg Leu Val 1 5 10 15 Ala Glu Ala Asp Glu Gly Gly Pro Ser Ala Ile Thr Gly Met Gly Leu 20 25 30 Cys Phe Arg Cys Leu Leu Phe Ser Phe Ser Gly Arg Ser Gly Val Glu 35 40 45 Gly Gly Arg Val Asp Leu Asn Val Phe Gly Ser Leu Gly Leu Gln Pro 50 55 60 Trp Ile Gly Ser Ser Arg Cys Trp Gly Gly Pro Cys Ser Ser Ala Leu 65 70 75 80 Arg Cys Gly Trp Phe Ser Ser Trp Pro Pro Pro Ser Lys Ser Ala Ile 85 90 95 Pro Ile Gly Gly Gly Ser Arg Gly Ala Gly Arg Val Ser Arg Trp Pro 100 105 110 Pro Pro His Trp Leu Glu Ala Trp Arg Val Ser Pro Arg Pro Leu Ser 115 120 125 Pro Leu Ser Pro Ala Thr Phe Gly Arg Gly Phe Ile Ala Val Ala Val 130 135 140 Ile Pro Gly Leu Trp Ala Arg Gly Arg Gly Cys Ser Ser Asp Arg Leu 145 150 155 160 Pro Arg Pro Ala Gly Pro Ala Arg Arg Gln Phe Gln Ala Ala Ser Leu 165 170 175 Leu Thr Arg Gly Trp Gly Arg Ala Trp Pro Trp Lys Gln Ile Leu Lys 180 185 190 Glu Leu Asp Glu Cys Tyr Glu Arg Phe Ser Arg Glu Thr Asp Gly Ala 195 200 205 Gln Lys Arg Arg Met Leu His Cys Val Gln Arg Ala Leu Ile Arg Ser 210 215 220 Gln Glu Leu Gly Asp Glu Lys Ile Gln Ile Val Ser Gln Met Val Glu 225 230 235 240 Leu Val Glu Asn Arg Thr Arg Gln Val Asp Ser His Val Glu Leu Phe 245 250 255 Glu Ala Gln Gln Glu Leu Gly Asp Thr Ala Gly Asn Ser Gly Lys Ala 260 265 270 Gly Ala Asp Arg Pro Lys Gly Glu Ala Ala Ala Gln Ala Asp Lys Pro 275 280 285 Asn Ser Lys Arg Ser Arg Arg Gln Arg Asn Asn Glu Asn Arg Glu Asn 290 295 300 Ala Ser Ser Asn His Asp His Asp Asp Gly Ala Ser Gly Thr Pro Lys 305 310 315 320 Glu Lys Lys Ala Lys Thr Ser Lys Lys Lys Lys Arg Ser Lys Ala Lys 325 330 335 Ala Glu Arg Glu Ala Ser Pro Ala Asp Leu Pro Ile Asp Pro Asn Glu 340 345 350 Pro Thr Tyr Cys Leu Cys Asn Gln Val Ser Tyr Gly Glu Met Ile Gly 355 360 365 Cys Asp Asn Asp Glu Cys Pro Ile Glu Trp Phe His Phe Ser Cys Val 370 375 380 Gly Leu Asn His Lys Pro Lys Gly Lys Trp Tyr Cys Pro Lys Cys Arg 385 390 395 400 Gly Glu Asn Glu Lys Thr Met Asp Lys Ala Leu Glu Lys Ser Lys Lys 405 410 415 Glu Arg Ala Tyr Asn Arg 420 3 2897 DNA Homo sapiens CDS (873)..(1712) 3 gcgagttgcg gtagttgctg tgtaccatgg tctcggaggt ttctgtcccg cggcccgtta 60 ggtcctggtc gggttttcag cgaagcaggc cgctcccctg cgtttcccag cgggcgtgct 120 gtgccgccca acaggctctg cctccaagtg ccaaaaactc ctagtaaagt ttgcgcctcg 180 cccgccgtcc acaccccagc ggccctgacg ctgtcccctc cgcgaccctc gcctctggaa 240 aaagtgacag gcaaggccac gcccccgcga gggccggcct cgagcccgca gcccccaggg 300 cctgggacgg tgaggggcgt gaatgcggcg gggggcgggg ccgttgccgg gggagggggc 360 cggggcgcat gcgcgctgcg cagcggggct gaatgtttcc caagtgtttg aaactggtat 420 ttgggttttc cacgttggac aagtgcggct cggcggccag cggagcgcgc cccttcccgc 480 tgcccgctcc gctcctctct tctacccagc ccagtgggcg agtgggcagc ggcggccgcg 540 gcgctgggcc ctctcccgcc ggtgtgtgcg cgctcgtacg cgcggccccc ggcgccagcc 600 ccgccgcctg agagggggcc tgcgccgccg gccggggcgt gcgcccggga gccaccgcca 660 ccgcggcccg cgccctcagg cgctggggtc cccgcggacc cggaggcggc ggacgggctc 720 ggcagatgta gccgccgggc cgaagcagga gccggcgggg gggcgccggg agagcgaggg 780 ctttgcattt tgcagtgcta ttttttgagg ggggcggggg gtggaggaag cggaaagccg 840 cgccgagtcg ccggggacct ccggggtgaa cc atg ttg agt cct gcc aac ggg 893 Met Leu Ser Pro Ala Asn Gly 1 5 gag cag ctc cac ctg gtg aac tat gtg gag gac tac ctg gac tcc atc 941 Glu Gln Leu His Leu Val Asn Tyr Val Glu Asp Tyr Leu Asp Ser Ile 10 15 20 gag tcc ctg cct ttc gac ttg cag aga aat gtc tcg ctg atg cgg gag 989 Glu Ser Leu Pro Phe Asp Leu Gln Arg Asn Val Ser Leu Met Arg Glu 25 30 35 atc gac gcg aaa tac caa gag atc ctg aag gag cta gac gag tgc tac 1037 Ile Asp Ala Lys Tyr Gln Glu Ile Leu Lys Glu Leu Asp Glu Cys Tyr 40 45 50 55 gag cgc ttc agt cgc gag aca gac ggg gcg cag aag cgg cgg atg ctg 1085 Glu Arg Phe Ser Arg Glu Thr Asp Gly Ala Gln Lys Arg Arg Met Leu 60 65 70 cac tgt gtg cag cgc gcg ctg atc cgc agc cag gag ctg ggc gac gag 1133 His Cys Val Gln Arg Ala Leu Ile Arg Ser Gln Glu Leu Gly Asp Glu 75 80 85 aag atc cag atc gtg agc cag atg gtg gag ctg gtg gag aac cgc acg 1181 Lys Ile Gln Ile Val Ser Gln Met Val Glu Leu Val Glu Asn Arg Thr 90 95 100 cgg cag gtg gac agc cac gtg gag ctg ttc gag gcg cag cag gag ctg 1229 Arg Gln Val Asp Ser His Val Glu Leu Phe Glu Ala Gln Gln Glu Leu 105 110 115 ggc gac aca gcg ggc aac agc ggc aag gct ggc gcg gac agg ccc aaa 1277 Gly Asp Thr Ala Gly Asn Ser Gly Lys Ala Gly Ala Asp Arg Pro Lys 120 125 130 135 ggc gag gcg gca gcg cag gct gac aag ccc aac agc aag cgc tca cgg 1325 Gly Glu Ala Ala Ala Gln Ala Asp Lys Pro Asn Ser Lys Arg Ser Arg 140 145 150 cgg cag cgc aac aac gag aac cgt gag aac gcg tcc agc aac cac gac 1373 Arg Gln Arg Asn Asn Glu Asn Arg Glu Asn Ala Ser Ser Asn His Asp 155 160 165 cac gac gac ggc gcc tcg ggc aca ccc aag gag aag aag gcc aag acc 1421 His Asp Asp Gly Ala Ser Gly Thr Pro Lys Glu Lys Lys Ala Lys Thr 170 175 180 tcc aag aag aag aag cgc tcc aag gcc aag gcg gag cga gag gcg tcc 1469 Ser Lys Lys Lys Lys Arg Ser Lys Ala Lys Ala Glu Arg Glu Ala Ser 185 190 195 cct gcc gac ctc ccc atc gac ccc aac gaa ccc acg tac tgt ctg tgc 1517 Pro Ala Asp Leu Pro Ile Asp Pro Asn Glu Pro Thr Tyr Cys Leu Cys 200 205 210 215 aac cag gtc tcc tat ggg gag atg atc ggc tgc gac aac gac gag tgc 1565 Asn Gln Val Ser Tyr Gly Glu Met Ile Gly Cys Asp Asn Asp Glu Cys 220 225 230 ccc atc gag tgg ttc cac ttc tcg tgc gtg ggg ctc aat cat aaa ccc 1613 Pro Ile Glu Trp Phe His Phe Ser Cys Val Gly Leu Asn His Lys Pro 235 240 245 aag ggc aag tgg tac tgt ccc aag tgc cgg ggg gag aac gag aag acc 1661 Lys Gly Lys Trp Tyr Cys Pro Lys Cys Arg Gly Glu Asn Glu Lys Thr 250 255 260 atg gac aaa gcc ctg gag aaa tcc aaa aaa gag agg gct tac aac agg 1709 Met Asp Lys Ala Leu Glu Lys Ser Lys Lys Glu Arg Ala Tyr Asn Arg 265 270 275 tag tttgtggaca ggcgcctggt gtgaggagga caaaataaac cgtgtattta 1762 280 ttacattgct gcctttgttg aggtgcaagg agtgtaaaat gtatattttt aaagaatgtt 1822 agaaaaggaa ccattccttt catagggatg gcagtgattc tgtttgcctt ttgttttcat 1882 tggtacacgt gtaacaagaa agtggtctgt ggatcagcat tttagaaact acaaatatag 1942 gtttgattca acacttaagt ctcagactga tttcttgcgg gaggaggggg actaaactca 2002 acctaacaca ttaaatgtgg aaggaaaata tttcatttag cttttttatt ttaatacaag 2062 taatattatt actttatgaa caattttttt taattggcca tgtcgccaaa aatacagcct 2122 atagtaaatg tgtttcttgc tgccatgatg tatatccata taacaattca gtaacaaagg 2182 tttaaagttt gaagattatt ttttaaaaag gtaaatggtt aaattttaca tgacagatat 2242 tttatttatt ggcctgttcc ccaaatggcc attttaaaat gcttgggtac acttctctta 2302 agtggtctag tcaaggaacc tcaagtcatg cttttgctat caccaatcat agtgtaccca 2362 tctttaattt atatcaggtg tataaatgta catttccaaa tgaacttgca cttgttatat 2422 tataattgga agtgcagtca gcagatgctg ttgtgaagct aatgtcacaa ttatgtgcaa 2482 aggtgtgctt cctgctgtat gtgagctgta aaaatgttac gtgaagaaat aaatgaaact 2542 tggccagttt gttcctctag tagtatattt aattttgaca taagtaactt ttaaaatttg 2602 tcttaaaaat ttatacacca gcaatttaga caaagcctta agcaaatttt gtattattgt 2662 tctcacttat tattaataat gaagtagaag ttacttaatt gccagcaaat aaatacgtgt 2722 caaaaaagaa tctgtattca gaccctgggt caggaaatta ctgcccactt gtcaagttca 2782 gcccaccatc tgtttgaaca ttatatgaag tttaaatttt agtgtccata aataaagttt 2842 cagcggaaca caaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaa 2897 4 279 PRT Homo sapiens 4 Met Leu Ser Pro Ala Asn Gly Glu Gln Leu His Leu Val Asn Tyr Val 1 5 10 15 Glu Asp Tyr Leu Asp Ser Ile Glu Ser Leu Pro Phe Asp Leu Gln Arg 20 25 30 Asn Val Ser Leu Met Arg Glu Ile Asp Ala Lys Tyr Gln Glu Ile Leu 35 40 45 Lys Glu Leu Asp Glu Cys Tyr Glu Arg Phe Ser Arg Glu Thr Asp Gly 50 55 60 Ala Gln Lys Arg Arg Met Leu His Cys Val Gln Arg Ala Leu Ile Arg 65 70 75 80 Ser Gln Glu Leu Gly Asp Glu Lys Ile Gln Ile Val Ser Gln Met Val 85 90 95 Glu Leu Val Glu Asn Arg Thr Arg Gln Val Asp Ser His Val Glu Leu 100 105 110 Phe Glu Ala Gln Gln Glu Leu Gly Asp Thr Ala Gly Asn Ser Gly Lys 115 120 125 Ala Gly Ala Asp Arg Pro Lys Gly Glu Ala Ala Ala Gln Ala Asp Lys 130 135 140 Pro Asn Ser Lys Arg Ser Arg Arg Gln Arg Asn Asn Glu Asn Arg Glu 145 150 155 160 Asn Ala Ser Ser Asn His Asp His Asp Asp Gly Ala Ser Gly Thr Pro 165 170 175 Lys Glu Lys Lys Ala Lys Thr Ser Lys Lys Lys Lys Arg Ser Lys Ala 180 185 190 Lys Ala Glu Arg Glu Ala Ser Pro Ala Asp Leu Pro Ile Asp Pro Asn 195 200 205 Glu Pro Thr Tyr Cys Leu Cys Asn Gln Val Ser Tyr Gly Glu Met Ile 210 215 220 Gly Cys Asp Asn Asp Glu Cys Pro Ile Glu Trp Phe His Phe Ser Cys 225 230 235 240 Val Gly Leu Asn His Lys Pro Lys Gly Lys Trp Tyr Cys Pro Lys Cys 245 250 255 Arg Gly Glu Asn Glu Lys Thr Met Asp Lys Ala Leu Glu Lys Ser Lys 260 265 270 Lys Glu Arg Ala Tyr Asn Arg 275 5 210 PRT Homo sapiens 5 Met Leu His Cys Val Gln Arg Ala Leu Ile Arg Ser Gln Glu Leu Gly 1 5 10 15 Asp Glu Lys Ile Gln Ile Val Ser Gln Met Val Glu Leu Val Glu Asn 20 25 30 Arg Thr Arg Gln Val Asp Ser His Val Glu Leu Phe Glu Ala Gln Gln 35 40 45 Glu Leu Gly Asp Thr Ala Gly Asn Ser Gly Lys Ala Gly Ala Asp Arg 50 55 60 Pro Lys Gly Glu Ala Ala Ala Gln Ala Asp Lys Pro Asn Ser Lys Arg 65 70 75 80 Ser Arg Arg Gln Arg Asn Asn Glu Asn Arg Glu Asn Ala Ser Ser Asn 85 90 95 His Asp His Asp Asp Gly Ala Ser Gly Thr Pro Lys Glu Lys Lys Ala 100 105 110 Lys Thr Ser Lys Lys Lys Lys Arg Ser Lys Ala Lys Ala Glu Arg Glu 115 120 125 Ala Ser Pro Ala Asp Leu Pro Ile Asp Pro Asn Glu Pro Thr Tyr Cys 130 135 140 Leu Cys Asn Gln Val Ser Tyr Gly Glu Met Ile Gly Cys Asp Asn Asp 145 150 155 160 Glu Cys Pro Ile Glu Trp Phe His Phe Ser Cys Val Gly Leu Asn His 165 170 175 Lys Pro Lys Gly Lys Trp Tyr Cys Pro Lys Cys Arg Gly Glu Asn Glu 180 185 190 Lys Thr Met Asp Lys Ala Leu Glu Lys Ser Lys Lys Glu Arg Ala Tyr 195 200 205 Asn Arg 210 

We claim:
 1. A monoclonal antibody which specifically recognizes an epitope of an ING1 protein.
 2. The antibody of claim 1 wherein the antibody is selected from the group consisting of CAb1, CAb2, CAb3, CAb4, CAb5, CAb6, CAb7, CAb8, CAb9 and CAb10.
 3. The antibody of claim 1 wherein the antibody is not CAb1.
 4. The antibody of claim 3 wherein the antibody is selected from the group consisting of CAb2, CAb3, CAb4, CAb5, CAb6, CAb7, CAb8, CAb9 and Cab10.
 5. A cell producing the antibody of claim
 1. 6. A cell producing the antibody of claim
 2. 7. A cell producing the antibody of claim
 3. 8. A cell producing the antibody of claim
 4. 9. A method of detecting an ING1 protein in a cell using anti-ING1 monoclonal antibodies, comprising: (a) selecting a cell; (b) applying to the cell, extract of the cell, or a form of the cell suitable for the detection of the ING1 protein an anti-ING1 monoclonal antibody or a combination of anti-ING1 monoclonal antibodies in an amount sufficient to detect the ING1 in said cell; and (c) detecting the ING1 protein.
 10. The method of claim 9 further comprising the steps of: (d) repeating step (b) wherein the monoclonal antibody or combination of monoclonal antibodies is pre-treated with an ING1 protein prior to application to the cell, extract of the cell, or a form of the cell suitable for the detection of the ING1 protein; (e) observing the result of step (d); and (f) comparing the detection level of step (c) to that of step (e).
 11. The method of claim 9 wherein the anti-ING1 monoclonal antibody is selected from the group consisting of CAb2, CAb3, CAb4, CAb5, CAb6, CAb7, CAb8, CAb9 and CAb10.
 12. The method of claim 9 wherein the combination of anti-ING1 monoclonal antibodies is a combination of two or more antibodies selected from the group consisting of CAb1, CAb2, CAb3, CAb4, CAb5, CAb6, CAb7, CAb8, CAb9 and CAb10.
 13. The method of claim 12 wherein the combination of anti-ING1 monoclonal antibodies is a mixture of CAb1, CAb2, CAb3, CAb4, CAb5, CAb6, CAb7, CAb8 and CAb9.
 14. The method of claim 9 wherein the ING1 protein is ectopically expressed in the cell.
 15. The method of claim 9 wherein the ING1 protein is endogenously expressed in the cell.
 16. A method of detecting at least two different isoforms of ING1 with monoclonal antibodies, comprising using an anti-ING1 monoclonal antibody or a combination of anti-ING1 monoclonal antibodies under conditions which result in the detection of at least two isoforms of ING1.
 17. The method of claim 16 wherein the combination of anti-ING1 monoclonal antibodies is a combination of two or more antibodies selected from the group consisting of CAb1, CAb2, CAb3, CAb4, CAb5, CAb6, CAb7, CAb8, CAb9 and Cab10.
 18. The method of claim 17 wherein the combination of anti-ING1 monoclonal antibodies is a combination of CAb1, CAb2, CAb3 and Cab4.
 19. The method of claim 16 wherein the isoforms of ING1 are ectopically expressed in a cell.
 20. The method of claim 16 wherein the isoforms of ING1 are endogenously expressed in a cell.
 21. A kit comprising: (a) a monoclonal antibody against an ING1 protein or a combination of monoclonal antibodies against an ING1 protein; and (b) a secondary antibody which recognizes the monoclonal antibody or antibodies.
 22. The kit of claim 21 which is useful in detecting the ING1 protein in an immunofluorescence assay.
 23. The kit of claim 21 which is useful in detecting the ING 1 protein in a Western blot assay.
 24. A method of diagnosing a disease or medical condition in an animal associated with aberrant levels of an ING1 protein, comprising determining levels of the ING1 protein with a monoclonal antibody or a combination of monoclonal antibodies which is capable of recognizing the ING1 protein.
 25. The method of claim 24 wherein the disease is a tumor.
 26. The method of claim 24 wherein the levels of the ING1 protein is determined using a sample obtained from the animal.
 27. The method of claim 24 wherein the animal is a human. 